One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...
A phase 3 trial found that PSMA PET-CT after equivocal MRI halves the prostate biopsy rate in men at high clinical risk for prostate cancer. In men with high clinical risk and equivocal prostate ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive ...
COBRA: Assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy. Impact of ...
New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...
Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results